Cargando…

Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (PDAC)

BACKGROUND: Raf-1 kinase inhibitor protein (RKIP) has emerged as a significant metastatic suppressor in a variety of human cancers and is known to inhibit Ras/Raf/MEK/ERK signaling. By suppressing the activation of the NFkB/SNAIL circuit, RKIP can regulate the induction of epithelial-mesenchymal tra...

Descripción completa

Detalles Bibliográficos
Autores principales: Karamitopoulou, Eva, Zlobec, Inti, Gloor, Beat, Kondi-Pafiti, Agathi, Lugli, Alessandro, Perren, Aurel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898115/
https://www.ncbi.nlm.nih.gov/pubmed/24330423
http://dx.doi.org/10.1186/1479-5876-11-311
_version_ 1782300363076927488
author Karamitopoulou, Eva
Zlobec, Inti
Gloor, Beat
Kondi-Pafiti, Agathi
Lugli, Alessandro
Perren, Aurel
author_facet Karamitopoulou, Eva
Zlobec, Inti
Gloor, Beat
Kondi-Pafiti, Agathi
Lugli, Alessandro
Perren, Aurel
author_sort Karamitopoulou, Eva
collection PubMed
description BACKGROUND: Raf-1 kinase inhibitor protein (RKIP) has emerged as a significant metastatic suppressor in a variety of human cancers and is known to inhibit Ras/Raf/MEK/ERK signaling. By suppressing the activation of the NFkB/SNAIL circuit, RKIP can regulate the induction of epithelial-mesenchymal transition (EMT). The aim of this study was to evaluate RKIP expression and to determine its association with clinicopathological features, including EMT in form of tumor budding in pancreatic ductal adenocarcinoma (PDAC). METHODS: Staining for RKIP was performed on a multipunch Tissue Microarray (TMA) of 114 well-characterized PDACs with clinico-pathological, follow-up and adjuvant therapy information. RKIP-expression was assessed separately in the main tumor body and in the tumor buds. Another 3 TMAs containing normal pancreatic tissue, precursor lesions (Pancreatic Intraepithelial Neoplasia, PanINs) and matched lymph node metastases were stained in parallel. Cut-off values were calculated by receiver operating characteristic (ROC) curve analysis. RESULTS: We found a significant progressive loss of RKIP expression between normal pancreatic ductal epithelia (average: 74%), precursor lesions (PanINs; average: 37%), PDAC (average 20%) and lymph node metastases (average 8%, p < 0.0001). RKIP expression was significantly lower in tumor buds (average: 6%) compared to the main tumor body (average 20%; p < 0.005). RKIP loss in the tumor body was marginally associated with advanced T-stage (p = 0.0599) as well as high-grade peritumoral (p = 0.0048) and intratumoral budding (p = 0.0373). RKIP loss in the buds showed a clear association with advanced T stage (p = 0.0089). CONCLUSIONS: The progressive loss of RKIP seems to play a major role in the neoplastic transformation of pancreas, correlates with aggressive features in PDAC and is associated with the presence of EMT in form of tumor budding.
format Online
Article
Text
id pubmed-3898115
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38981152014-01-23 Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (PDAC) Karamitopoulou, Eva Zlobec, Inti Gloor, Beat Kondi-Pafiti, Agathi Lugli, Alessandro Perren, Aurel J Transl Med Research BACKGROUND: Raf-1 kinase inhibitor protein (RKIP) has emerged as a significant metastatic suppressor in a variety of human cancers and is known to inhibit Ras/Raf/MEK/ERK signaling. By suppressing the activation of the NFkB/SNAIL circuit, RKIP can regulate the induction of epithelial-mesenchymal transition (EMT). The aim of this study was to evaluate RKIP expression and to determine its association with clinicopathological features, including EMT in form of tumor budding in pancreatic ductal adenocarcinoma (PDAC). METHODS: Staining for RKIP was performed on a multipunch Tissue Microarray (TMA) of 114 well-characterized PDACs with clinico-pathological, follow-up and adjuvant therapy information. RKIP-expression was assessed separately in the main tumor body and in the tumor buds. Another 3 TMAs containing normal pancreatic tissue, precursor lesions (Pancreatic Intraepithelial Neoplasia, PanINs) and matched lymph node metastases were stained in parallel. Cut-off values were calculated by receiver operating characteristic (ROC) curve analysis. RESULTS: We found a significant progressive loss of RKIP expression between normal pancreatic ductal epithelia (average: 74%), precursor lesions (PanINs; average: 37%), PDAC (average 20%) and lymph node metastases (average 8%, p < 0.0001). RKIP expression was significantly lower in tumor buds (average: 6%) compared to the main tumor body (average 20%; p < 0.005). RKIP loss in the tumor body was marginally associated with advanced T-stage (p = 0.0599) as well as high-grade peritumoral (p = 0.0048) and intratumoral budding (p = 0.0373). RKIP loss in the buds showed a clear association with advanced T stage (p = 0.0089). CONCLUSIONS: The progressive loss of RKIP seems to play a major role in the neoplastic transformation of pancreas, correlates with aggressive features in PDAC and is associated with the presence of EMT in form of tumor budding. BioMed Central 2013-12-14 /pmc/articles/PMC3898115/ /pubmed/24330423 http://dx.doi.org/10.1186/1479-5876-11-311 Text en Copyright © 2013 Karamitopoulou et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Karamitopoulou, Eva
Zlobec, Inti
Gloor, Beat
Kondi-Pafiti, Agathi
Lugli, Alessandro
Perren, Aurel
Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (PDAC)
title Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (PDAC)
title_full Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (PDAC)
title_fullStr Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (PDAC)
title_full_unstemmed Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (PDAC)
title_short Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (PDAC)
title_sort loss of raf-1 kinase inhibitor protein (rkip) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (pdac)
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898115/
https://www.ncbi.nlm.nih.gov/pubmed/24330423
http://dx.doi.org/10.1186/1479-5876-11-311
work_keys_str_mv AT karamitopouloueva lossofraf1kinaseinhibitorproteinrkipisstronglyassociatedwithhighgradetumorbuddingandcorrelateswithanaggressivephenotypeinpancreaticductaladenocarcinomapdac
AT zlobecinti lossofraf1kinaseinhibitorproteinrkipisstronglyassociatedwithhighgradetumorbuddingandcorrelateswithanaggressivephenotypeinpancreaticductaladenocarcinomapdac
AT gloorbeat lossofraf1kinaseinhibitorproteinrkipisstronglyassociatedwithhighgradetumorbuddingandcorrelateswithanaggressivephenotypeinpancreaticductaladenocarcinomapdac
AT kondipafitiagathi lossofraf1kinaseinhibitorproteinrkipisstronglyassociatedwithhighgradetumorbuddingandcorrelateswithanaggressivephenotypeinpancreaticductaladenocarcinomapdac
AT luglialessandro lossofraf1kinaseinhibitorproteinrkipisstronglyassociatedwithhighgradetumorbuddingandcorrelateswithanaggressivephenotypeinpancreaticductaladenocarcinomapdac
AT perrenaurel lossofraf1kinaseinhibitorproteinrkipisstronglyassociatedwithhighgradetumorbuddingandcorrelateswithanaggressivephenotypeinpancreaticductaladenocarcinomapdac